Composición y calidad de la leche en función de la etapa de lactancia y de la paridad

The purpose of this work was to evaluate the relationship among lactation order and days in milking with milk production, composition and somatic cells count (SCC) from Holstein cows and also verify the efficiency of "California Mastitis Test” (CMT) to detect high scores of SCC. Milk samples were collected from the Experimental Farm of Iguatemi located in Maringa, Parana State, from 2008 to 2009. Regression analyzes were performed by a computer system R (2009) in order to verify the behavior of production and milk components as a function of days of lactation order and using the mixed model methodology, considering animal and day of milk control as random. To evaluate the efficiency of CMT test in detecting high SCC was considered negative binomial distribution for the response variable, because it is data that exhibit over dispersion, using the methodology of generalized linear models. It was found that milk production increases and milk fat decreases by the lactation order. Milk protein increases with the days in milking because milk production is decreased. It was concluded that milk production and quality are closely connected to the lactation order and days in milking and CMT performed on farm is positively linked with CCS.El objetivo de este estudio fue evaluar la relación entre el orden y los días de lactancia con la producción, composición y conteo de células somáticas (CCS) en leche de vacas Holstein, así como comprobar la eficacia de la prueba California para Mastitis (CMT) detectando alto CCS. Se tomaron muestras de leche del rebaño de la Hacienda Experimental de Iguatemi, Maringá-PR, en un periodo comprendido entre 2008 y 2009. Fueron realizados análisis de regresión utilizando el programa estadístico R (2009) con el fin de verificar el comportamiento de la producción y los componentes de la leche en función de los días y orden de lactancia utilizando la metodología de modelos lineares mixtos, considerando el animal y día de control lechero como aleatorios. Para evaluar la eficacia de la prueba de CMT para detectar alto CCS se consideró distribución binomial negativa para la variable respuesta, ya que los datos mostraron sobredispersión utilizando la metodología de modelos lineales generalizados. Se encontró que a medida que la producción de leche aumenta, el porcentaje de grasa en la leche disminuye, siendo diferente en cada orden de lactancia. El porcentaje de proteína aumenta con el periodo de lactación, mientas disminuye la producción. Se concluye que la producción y la calidad de la leche están estrechamente relacionadas con el orden y los días de lactación, la prueba CMT tiene relación positiva con el CCS

Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice

The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are either approved (remdesivir), emergency approved (dexamethasone, baricitinib, paxlovid, and molnupiravir), or in advanced clinical trials. Vandetanib is a kinase inhibitor which targets the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), as well as the RET-tyrosine kinase. In the current study, it was tested in different cell lines and showed promising results on inhibition versus the toxic effect on A549-hACE2 cells (IC500.79 μM) while also showing a reduction of >3 log TCID50/mL for HCoV-229E. The in vivo efficacy of vandetanib was assessed in a mouse model of SARS-CoV-2 infection and statistically significantly reduced the levels of IL-6, IL-10, and TNF-α and mitigated inflammatory cell infiltrates in the lungs of infected animals but did not reduce viral load. Vandetanib also decreased CCL2, CCL3, and CCL4 compared to the infected animals. Vandetanib additionally rescued the decreased IFN-1β caused by SARS-CoV-2 infection in mice to levels similar to that in uninfected animals. Our results indicate that the FDA-approved anticancer drug vandetanib is worthy of further assessment as a potential therapeutic candidate to block the COVID-19 cytokine storm